<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01709903</url>
  </required_header>
  <id_info>
    <org_study_id>CQVA149A2331</org_study_id>
    <nct_id>NCT01709903</nct_id>
  </id_info>
  <brief_title>A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149</brief_title>
  <official_title>A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Argentina: Human Research Bioethics Committee</authority>
    <authority>Argentina: Ministry of Health</authority>
    <authority>Brazil: Ethics Committee</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Chile: Comisi?n Nacional de Investigaci?n Cient?fica y Tecnol?gica</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>China: Ethics Committee</authority>
    <authority>China: Ministry of Health</authority>
    <authority>China: Food and Drug Administration</authority>
    <authority>Taiwan: Center for Drug Evaluation</authority>
    <authority>Taiwan: Department of Health</authority>
    <authority>Taiwan: Institutional Review Board</authority>
    <authority>Taiwan: National Bureau of Controlled Drugs</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the non-inferiority of QVA149 110/50 µg o.d. to fluticasone/salmeterol 500/50
      µg b.i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours
      15 min and 23 hours 45 min post QVA149 dose) following 26 weeks of treatment in patients
      with moderate to severe COPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the non-inferiority of QVA149 110/50 µg o.d. to fluticasone/salmeterol 500/50
      µg b.i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours
      15 min and 23 hours 45 min post QVA149 dose) following 26 weeks of treatment in patients
      with moderate to severe COPD.

      The study population will consist of approximate 736 male and female adults (age 40 years
      and greater) with a clinical diagnosis of stable COPD [GOLD (2010)] and a smoking history of
      at least 10 pack years. It is anticipated that approximately 981 patients will need to be
      screened in order to randomize 736 patients into 2 treatment arms of the study with an equal
      randomization ratio, meaning QVA149 (368 patients), fluticasone/salmeterol (368 patients).
      Treatment randomization will be stratified by current/ex-smoker status and prior ICS use. It
      is intended that 552 patients will complete the study at Week 26 without major protocol
      deviations. Dropouts will not be replaced.

      This will be a multi-national study, including China, and at least two other countries.

      Standardization FEV1 AUC0-12h will be performed in a subgroup of around 100 patients (50
      patients per treatment arm) in pre-selected centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in one second (FEV1)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean of 23 hours 15 min and 23 hours 45 min post QVA149 dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC) 0-12 hours</measure>
    <time_frame>12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The trapezoidal rule will be used to calculate Forced Expiratory Volume in one second Area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in one second (FEV1) and Forced Vital Capacity (FVC)</measure>
    <time_frame>12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Average of Trough Forced Expiratory Volume in one second (FEV1) and Forced Vital Capacity (FVC) at 23 hours 15 min and the 23 hours 45 min post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Forced Expiratory Volume in one second (FEV1) Area under the curve (AUC) 0-4 hours</measure>
    <time_frame>12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The trapezoidal rule will be used to calculate Forced Expiratory Volume in one second Area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total score of St.George Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dyspnea will be measured at baseline using the baseline dyspnea index (BDI) and during the treatment period using the transitional dyspnea index (TDI), which captures changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of puffs of rescue medication taken in the previous 12 hours will be recorded in the Patient Diary in the morning and evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms reported using e-diary over 12 and 26 weeks of treatment</measure>
    <time_frame>12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be recorded in the Patient Diary in the morning and evening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Electrocardiograms(ECGs), laboratory tests, blood pressure, heart rate and adverse events including Chronic Obstructive Pulmonary Disease (COPD) exacerbations and oral candidiasis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">747</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>QVA149</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluticasone/salmeterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVA149</intervention_name>
    <description>QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).</description>
    <arm_group_label>QVA149</arm_group_label>
    <other_name>Experimental: QVA149</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/salmeterol</intervention_name>
    <description>Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.</description>
    <arm_group_label>fluticasone/salmeterol</arm_group_label>
    <other_name>Comparator: Fluticasone/salmeterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pacebo to QVA149</intervention_name>
    <description>Placebo to QVA149 with SDDPI</description>
    <arm_group_label>fluticasone/salmeterol</arm_group_label>
    <other_name>Experimental: QVA149</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to fluticasone/salmeterol</intervention_name>
    <description>Placebo to fluticasone/salmeterol with Accuhaler</description>
    <arm_group_label>QVA149</arm_group_label>
    <other_name>Comparator: fluticasone/salmeterol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate to severe stable COPD (Stage II or Stage III) according to
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guideline.

        Current or ex-smokers who have a smoking history of at least 10 pack years. Patients with
        a post-bronchodilator Forced Expiratory Volume in one second (FEV1) ≥ 30% and &lt; 80% of the
        predicted normal, and post-bronchodilator FEV1/FVC &lt; 0.7.

        Modified Medical Research Council (mMRC) grade of at least 2 at Visit 2.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive Human Chorionic Gonadotropin (hCG) laboratory test.

        Patents with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH),
        bladder-neck obstruction, moderate to severe renal impairment or urinary retention. BPH
        patients who are stable on treatment can be considered.

        Patients with a history of long QT syndrome or whose QTc measured at run-in (Visit 2)
        (Fridericia method) is prolonged (&gt;450 ms for males and females) as confirmed by the
        central Electrocardiogram (ECG) assessor.

        Patients with Type I or uncontrolled Type II diabetes. Patients who have not achieved
        spirometry result at Visit 2 in accordance with American Thoracic Society/European
        Respiratory Society (ATS/ERS) criteria for acceptability and repeatability.

        Patients with, a) any history of asthma or, b) onset of respiratory symptoms prior to age
        40 years.

        Patients with concomitant pulmonary disease (e.g. lung fibrosis, primary bronchiectasis,
        sarcoidosis, interstitial lung disorder, pulmonary hypertension).

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1122</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>B8000XAV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1424BSF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rojas</city>
        <state>Buenos Aires</state>
        <zip>B2705XAE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000IFL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8431633</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viña del Mar</city>
        <state>Vina del Mar</state>
        <zip>2520024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>Piso 1</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha City</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jiangyin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan, ROC</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81346</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Ko</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Salmeterol</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone, salmeterol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
